[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638021":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":31,"responsibleParty":46,"collaborators":11,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":11,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":11,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":11,"overallStatus":67,"whyStopped":11,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Chengdu Kangnuoxing Biopharma,Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Group of Stapokibart Injection","EXPERIMENTAL",null,[13],"Biological: Stapokibart injection",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"BIOLOGICAL","Stapokibart injection","subcutaneous injection",[9],[21],{"name":22,"affiliation":23,"role":24},"Luo Zhang","Beijing Tongren Hospital, CMU","STUDY_CHAIR",[26],{"name":27,"role":28,"phone":29,"phoneExt":11,"email":30},"Qian Jia","CONTACT","028-88610620","clinicaltrial@keymedbio.com",[32],{"facility":23,"status":11,"city":33,"state":34,"zip":11,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Beijing","Beijing Municipality","China","CN",{"type":38,"coordinates":39},"Point",[40,41],116.39723,39.9075,{"lat":41,"lon":40},[44],{"name":27,"role":28,"phone":45,"phoneExt":11,"email":30},"86+028-88610620",{"type":47,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100638021","phase-2-study-of-stapokibart-injection-in-adolescent-subjects-with-seasonal-allergic-rhinitis-sar-100638021",false,"NCT07617324","Study of Stapokibart Injection in Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)","A Multicenter, Single-arm, Open-label Study to Evaluate the Safety and Pharmacokinetics of Stapokibart Injection in Adolescent Patients With SAR Under Background Therapy","Inclusion Criteria:\n\n* Voluntarily sign the Informed Consent Form.\n* Age ≥ 12 years old and \\\u003C18 years old, weight ≥ 40 kg.\n* With a diagnosis of SAR, with or without allergic conjunctivitis, and the SAR duration was ≥ 2 years.\n\nExclusion Criteria:\n\n* Not enough washing-out period for previous therapies.\n* With other poorly controlled serious diseases or chronic conditions.\n* With any conditions that are not suitable for participation in this study by investigators.","ALL","12 Years","18 Years",{"count":59,"type":60},15,"ESTIMATED","INTERVENTIONAL",[63],"PHASE2","This study is a multicenter, single-arm, open-label, phase II study to evaluate the safety, pharmacokinetics, and immunogenicity of Stapokibart injection in Adolescent Patients with SAR.",[66],"Seasonal Allergic Rhinitis (SAR)","NOT_YET_RECRUITING","2026-05-24",{"date":70,"type":71},"2026-06-01","ACTUAL",{"date":73,"type":60},"2026-06",{"date":75,"type":60},"2027-02",{"name":5,"class":6},1]